Shandong Lukang Pharmaceutical Co.,Ltd.
Shanghai Stock ExchangeTotal Valuation
Shandong Lukang Pharmaceutical Co.,Ltd. carries a market capitalization of 6.09B, placing it among publicly traded companies globally. Its enterprise value stands at 11.08B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 6.09B |
| Enterprise Value | 11.08B |
Share Statistics
Shandong Lukang Pharmaceutical Co.,Ltd. currently has 898.67M shares outstanding.
| Shares Outstanding | 898.67M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Shandong Lukang Pharmaceutical Co.,Ltd. trades at a trailing price-to-earnings ratio of 43.39. The price-to-sales ratio is 1.43, and the price-to-book ratio stands at 4.24.
| PE Ratio | 43.39 |
| PS Ratio | 1.43 |
| PB Ratio | 4.24 |
| P/TBV Ratio | 2.77 |
| P/FCF Ratio | 29.09 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Shandong Lukang Pharmaceutical Co.,Ltd. trades at an EV/EBITDA multiple of 24.70 and an EV/FCF ratio of 30.73. The EV/Sales ratio of 1.81 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 24.70 provides insight into valuation relative to core operating earnings.
| EV / Sales | 1.81 |
| EV / EBITDA | 24.70 |
| EV / EBIT | 24.70 |
| EV / FCF | 30.73 |
Financial Position
Shandong Lukang Pharmaceutical Co.,Ltd. maintains a current ratio of 1.25, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 71.01, indicating elevated leverage, while an interest coverage ratio of 6.20 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 1.25 |
| Quick Ratio | 0.23 |
| Debt / Equity | 71.01 |
| Debt / EBITDA | 6.48 |
| Interest Coverage | 6.20 |
Financial Efficiency
Shandong Lukang Pharmaceutical Co.,Ltd. posts a return on equity of 9.92 and a return on invested capital of 5.48.
| Return on Equity (ROE) | 9.92 |
| Return on Assets (ROA) | 2.27 |
| Return on Invested Capital (ROIC) | 5.48 |
| Return on Capital Employed (ROCE) | 5.02 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 3.74 |
Taxes
Over the trailing twelve months, Shandong Lukang Pharmaceutical Co.,Ltd. has paid 43.63M in income taxes, reflecting an effective tax rate of 17.05.
| Income Tax | 43.63M |
| Effective Tax Rate | 17.05 |
Stock Price Statistics
Shandong Lukang Pharmaceutical Co.,Ltd.'s stock has declined approximately -34.30233% over the past 52 weeks. The 50-day moving average sits at 7.70, while the 200-day moving average is 8.91.
| Beta (5Y) | N/A |
| 52-Week Price Change | -34.30233% |
| 50-Day Moving Average | 7.70 |
| 200-Day Moving Average | 8.91 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Shandong Lukang Pharmaceutical Co.,Ltd. generated 6.11B in revenue and converted that into 201.49M in net income, yielding earnings per share of 0.24. EBITDA reached 448.42M, while operating income came in at 448.42M.
| Revenue | 6.11B |
| Gross Profit | 1.47B |
| Operating Income | 448.42M |
| Pretax Income | 255.92M |
| Net Income | 201.49M |
| EBITDA | 448.42M |
| EBIT | 448.42M |
| Earnings Per Share (EPS) | 0.24 |
Balance Sheet
Shandong Lukang Pharmaceutical Co.,Ltd. holds 717.00M in cash and equivalents against 2.91B in total debt, resulting in a net debt position of 1.56B. Total book value stands at 2.06B, with working capital of 770.92M providing operational flexibility.
| Cash & Cash Equivalents | 717.00M |
| Total Debt | 2.91B |
| Net Debt | 1.56B |
| Equity (Book Value) | 2.06B |
| Book Value Per Share | 2.36 |
| Working Capital | 770.92M |
Cash Flow
After subtracting -300.46M in capital expenditures, free cash flow totaled -300.46M - equivalent to -0.34 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -300.46M |
| Free Cash Flow | -300.46M |
| FCF Per Share | -0.34 |
Margins
Shandong Lukang Pharmaceutical Co.,Ltd. operates with a gross margin of 24.01, reflecting its pricing power and cost economics. The operating margin of 7.34 and net profit margin of 3.30 provide insight into operational efficiency.
| Gross Margin | 24.01 |
| Operating Margin | 7.34 |
| Pretax Margin | 4.19 |
| Profit Margin | 3.30 |
| EBITDA Margin | 7.34 |
Dividends & Yields
The company's payout ratio of 106.79 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.27 |
| Dividend Yield | N/A |
| Payout Ratio | 106.79 |
| Shareholder Yield | 2.74 |
| FCF Yield | 3.44 |
Stock Splits
Shandong Lukang Pharmaceutical Co.,Ltd.'s most recent stock split took place on June 19, 2019 with a 10:13 split ratio.
| Last Split Date | 6/19/2019 |
| Split Ratio | 10:13 |
Scores
Shandong Lukang Pharmaceutical Co.,Ltd. posts an Altman Z-Score of 2.37, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.37 |